Archive
Every story, newest first.
Thursday, November 12, 2026
Commodities
Nigeria produced an average of 1.51 million barrels a day of crude oil in October, 101 percent of its 1.5 million barrel OPEC quota, meeting the target for a sixth consecutive month, the upstream regulator said.
Commodities
India has imported about 2.1 million barrels a day of crude from the Persian Gulf so far in November against 1.8 million from Russia, the first time Gulf volumes have led since the Iran war began, according to Kpler data reported by Bloomberg.
Commodities
Spot gold fell for a third straight day on Thursday, trading near 3868 dollars an ounce by late morning in New York after losing more than 1 percent on Wednesday, as traders fully priced a December Federal Reserve rate hike.
Commodities
Germany's government confirmed on Wednesday it will build a 24 terawatt hour state crisis gas reserve funded by user surcharges, after national storage ended October at 62 percent against a 70 percent target.
Life Sciences
Amsterdam-based VectorY added 74.5 million euros, or 83.5 million dollars, to its Series A, including a 30 million euro European Investment Bank convertible loan, to carry its ALS gene therapy through its Phase 1/2 readout.
Life Sciences
A Pan American Health Organization expert panel has determined that the United States has lost the measles elimination status it held since 2000, after the same strain circulated without a break for more than 12 months, with 5,412 confirmed cases reported in 2026.
Life Sciences
Neurosterix, the Addex spin-out, closed a 105 million dollar Series B to fund Phase 2 development of NTX-253, its oral M4 modulator for schizophrenia.
Life Sciences
AstraZeneca bought vaccine partner Omniose for undisclosed terms, Compass Pathways completed its psilocybin filing, and FDA review divisions are running 1,343 staff below their 2024 level.
Life Sciences
Johnson & Johnson said Caplyta cut mania scores 3.7 points more than placebo in Study 452, its second pivotal Phase 3 win in bipolar I mania.
Life Sciences
Beeline's oral afimetoran produced SRI-4 response rates of 64 to 68 percent against 34.4 percent on placebo at week 48 in detailed Phase 2 lupus data presented November 11.